Azevedo, R. S., Jen, W.-Y., Hammond, D., Haddad, F. G., Geppner, A., Issa, G. C., Sasaki, K., Senapati, J., Jabbour, E., Ravandi, F., Kantarjian, H. and Kadia, T. M. (2025) “Lower-intensity chemo-immunotherapy with cladribine, low-dose cytarabine, venetoclax and blinatumomab produces high response rates in patients with <i>BCR::ABL1</i&gt;-negative B-cell/myeloid mixed phenotype acute leukemia”, Haematologica. Pavia, Italy, 110(12), pp. 3129-3132. doi: 10.3324/haematol.2025.287932.